Nom du produit:4-chloroquinazoline

IUPAC Name:4-chloroquinazoline

CAS:5190-68-1
Formule moléculaire:C8H5ClN2
Pureté:97%
Numéro de catalogue:CM114974
Poids moléculaire:164.59

Unité d'emballage Stock disponible Prix($) Quantité
CM114974-5g in stock Ǚƈ
CM114974-10g in stock ǸƚǙ
CM114974-25g in stock ƚħŮ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:5190-68-1
Formule moléculaire:C8H5ClN2
Point de fusion:-
Code SMILES:ClC1=C2C=CC=CC2=NC=N1
Densité:
Numéro de catalogue:CM114974
Poids moléculaire:164.59
Point d'ébullition:281.0±13.0°C at 760 mmHg
N° Mdl:MFCD00228682
Stockage:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Quinazolines
Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

Column Infos

Bexotegrast
Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.